Presented at Cure SMA 2025 in Anaheim, California with neurologists at Nagoya University. The same assay was extended to screen for severe combined immunodeficiency from the same run.
ANAHEIM, Calif., July 1, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented research at Cure SMA 2025 on a point-of-care tool that screens newborns for spinal muscular atrophy (SMA) and, in an extended version of the same assay, for severe combined immunodeficiency (SCID). In a prospective study of 1,000 newborns, the tool's results agreed with confirmatory MLPA testing in every case, and results were available at the bedside within 1.5 hours of birth. Conventional screening has required one to two weeks after birth to return a result.
The work was done with Professor Masahisa Katsuno and Associate Professor Kentaro Sahashi of the Department of Neurology at Nagoya University. The presentation was titled "Development of a point-of-care dual screening tool for spinal muscular atrophy and severe combined immunodeficiency."
This newborn screening research, presented at a conference but not yet published in a peer-reviewed journal, is separate from Craif's urine microRNA cancer testing business and does not involve cancer detection. The tool is a research tool and has not been cleared, approved or authorized in any market.
What the study reported
- Turnaround. Conventional SMA screening has required one to two weeks after birth for a result to come back. The new tool uses a saliva sample, runs at the bedside, and returns a result within 1.5 hours.
- Agreement with confirmatory testing. In a prospective study of 1,000 newborns whose guardians consented, results from the new tool agreed with confirmatory MLPA testing in all cases.
- A single test for two conditions. The team also built an assay targeting TREC for SCID, and combined the two into one system that screens for SMA and SCID at the same time.
Why turnaround matters in SMA
SMA is a refractory disease in which motor neurons are impaired from birth. Recent treatments can improve motor function and survival, but their benefit is limited when treatment begins after symptoms appear, making detection and intervention while the infant is still asymptomatic critical.
The team set out to build an ultra-rapid SMA screening tool that an obstetric facility could run itself, and worked with participating institutions to assess whether it could be deployed in practice. The tool was designed so that SCID screening could run alongside SMA screening, and the feasibility of adding TREC detection to the same assay was tested.
How the study was run
At cooperating obstetric facilities, the team collected saliva and umbilical cord blood samples from 1,000 newborns already undergoing expanded newborn screening, with guardian consent. The team anonymized the samples and analyzed them with both the new tool and MLPA. Results agreed in every case.
The team then evaluated the combined SMA and SCID assay with TREC primers added. With optimized primer concentrations, the assay correctly and simultaneously distinguished low-TREC samples, defined as fewer than 10 TREC copies per reaction, from SMA-positive samples.
Unlike conventional methods, the tool requires no specialized laboratory instrument and can be run simply at the bedside within 1.5 hours of birth, which the team describes as a useful way to get the most out of treatment.
Craif plans a prospective study using clinical specimens for the kit that screens for SMA and SCID together. A short explanation of the SMA screening kit is available at https://youtu.be/epq3FLtY7uE
About Cure SMA 2025
Cure SMA 2025 is the annual professional meeting convened by Cure SMA, a US spinal muscular atrophy patient organization. It ran June 25 to June 27, 2025 in Anaheim, California. Details: https://www.curesma.org/sma-professional-meeting/
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
